Editas Medicine Reports Inducement Grant to New Chief Scientific Officer
July 25 2023 - 8:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome
editing company, today announced the grant of an inducement award
to the Company’s newly appointed Chief Scientific
Officer, Linda C. Burkly, Ph.D. In connection with Dr.
Burkly’s appointment, the Editas Medicine Board of Directors
approved a stock option grant to Dr. Burkly as an inducement
material to Dr. Burkly entering into employment
with Editas Medicine in accordance with Nasdaq Listing Rule
5635(c)(4). The stock option provides for the purchase of up
to 135,500 shares of Editas Medicine common stock at a
price of $8.66 per share, the closing price per share
of Editas Medicine common stock as reported by Nasdaq
on the date of grant, and vests over four years, with 25
percent of the shares vesting on the first anniversary of Dr.
Burkly’s employment start date, and the remainder vesting ratably
at the end of each subsequent month thereafter, subject to Dr.
Burkly’s continued service relationship with Editas
Medicine through the applicable vesting dates.
About Editas MedicineAs a
clinical-stage genome editing company, Editas Medicine is
focused on translating the power and potential of the CRISPR/Cas12a
and Cas9 genome editing systems into a robust pipeline of
treatments for people living with serious diseases around the
world. Editas Medicine aims to discover, develop,
manufacture, and commercialize transformative, durable, precision
genomic medicines for a broad class of diseases. Editas
Medicine is the exclusive licensee of Broad Institute’s Cas12a
patent estate and Broad Institute and Harvard
University’s Cas9 patent estates for human medicines. For the
latest information and scientific presentations, please visit
www.editasmedicine.com.
Media and Investor Contact
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2024 to May 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From May 2023 to May 2024